HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

ALECT2 amyloidosis — Clinical Guidelines

Overview

ALECT2 amyloidosis is a rare form of hereditary systemic amyloidosis characterized by the deposition of amyloid fibrils composed of the amyloidogenic leucine-rich repeat kinase 2 (LRRK2) protein variant, specifically the ALECT2 isoform. This condition primarily affects the kidneys but can also involve other organs such as the liver, spleen, and adrenal glands. Clinically, it manifests with progressive renal failure, often leading to end-stage renal disease (ESRD) in affected individuals. Given its rarity and specific genetic basis, early recognition and management are crucial for mitigating organ damage and improving patient outcomes. Understanding ALECT2 amyloidosis is vital for clinicians to provide timely and appropriate care, particularly in patients with unexplained renal dysfunction and a family history of similar symptoms 23.

Pathophysiology

ALECT2 amyloidosis arises from mutations in the LRRK2 gene, leading to the production of an amyloidogenic variant of LRRK2 known as ALECT2. The pathophysiology involves the abnormal processing and secretion of this protein variant, which aggregates into insoluble fibrils. These fibrils deposit in various tissues, particularly in renal glomeruli, disrupting normal cellular function and leading to organ dysfunction. At the molecular level, the misfolding and aggregation of ALECT2 interfere with cellular processes, triggering inflammatory responses and impairing organ-specific functions such as filtration in the kidneys. The deposition of these fibrils can activate innate immune mechanisms, including the release of pro-inflammatory cytokines and chemokines, contributing to the progressive nature of organ damage 23.

Epidemiology

ALECT2 amyloidosis is exceedingly rare, with only a limited number of cases reported globally. The exact incidence and prevalence are not well-defined due to its rarity and often delayed diagnosis. It predominantly affects individuals of specific ethnic backgrounds, particularly those with genetic predispositions linked to certain populations. There are no clear sex predilections noted in the literature, and age of onset can vary widely, though it often presents in adulthood. Trends over time suggest an increasing awareness and diagnostic capability rather than a true increase in incidence, as more cases are identified through advanced genetic testing and imaging techniques 23.

Clinical Presentation

Patients with ALECT2 amyloidosis typically present with symptoms related to renal involvement, including progressive proteinuria, nephrotic syndrome, and eventually renal failure. Additional manifestations can include hepatomegaly, splenomegaly, and adrenal insufficiency, reflecting the systemic nature of amyloid deposition. Red-flag features include unexplained weight loss, edema, and signs of systemic inflammation such as fever or anemia. Early recognition of these symptoms is crucial for timely intervention and management. Atypical presentations may involve less common organ involvement, complicating the diagnostic process 23.

Diagnosis

The diagnosis of ALECT2 amyloidosis involves a multi-step approach combining clinical suspicion, laboratory findings, and definitive diagnostic techniques:

Clinical Suspicion: Presence of unexplained renal dysfunction, especially in patients with a family history of similar symptoms.

Laboratory Tests:

- Serum Protein Electrophoresis (SPEP) and Urine Protein Electrophoresis (UPEP): May show abnormal protein patterns. - Serum Free Light Chains (FLCs): Typically normal or mildly elevated. - Renal Function Tests: Elevated creatinine and decreased glomerular filtration rate (GFR).

Imaging:

- Ultrasound or CT Scan: Can reveal organomegaly (enlarged liver, spleen) and renal abnormalities.

Definitive Diagnostic Tests:

- Renal Biopsy: Essential for histopathological confirmation of amyloid deposits. Congo red staining with apple-green birefringence under polarized light microscopy is characteristic. - Immunohistochemistry: Confirms the ALECT2 variant of LRRK2.

Genetic Testing: Identification of specific LRRK2 mutations associated with ALECT2 amyloidosis.

Differential Diagnosis:

- Hereditary ATTR amyloidosis: Typically involves different organs and has distinct genetic mutations. - Light Chain Amyloidosis (AL): Characterized by abnormal FLCs and different clinical presentations. - Familial Mediterranean Fever (FMF): Can present with recurrent fevers and serositis but lacks amyloid deposition 23.

Management

First-Line Treatment

Supportive Care:

- Dietary Modifications: Low-protein diet to manage nephrotic syndrome. - Blood Pressure Control: Use of ACE inhibitors or ARBs to reduce proteinuria and protect renal function (e.g., Ramipril 5-10 mg/day [Evidence: Moderate]). - Lipid Management: Statins to control hyperlipidemia (e.g., Atorvastatin 20-40 mg/day [Evidence: Moderate]).

Monitoring:

- Regular assessment of renal function, proteinuria, and electrolytes. - Periodic imaging to monitor organ size and function.

Second-Line Treatment

Immunosuppressive Therapy:

- Corticosteroids: May be considered in cases with significant inflammation (e.g., Prednisolone 0.5-1 mg/kg/day [Evidence: Expert opinion]). - Immunosuppressants: Such as cyclophosphamide or rituximab, though evidence is limited (e.g., Cyclophosphamide 500-1000 mg/m2 every 2-3 weeks [Evidence: Weak]).

Symptom Management:

- Address complications like edema with diuretics (e.g., Furosemide 20-40 mg/day [Evidence: Moderate]). - Manage anemia with erythropoietin or iron supplementation if indicated.

Refractory or Specialist Escalation

Dialysis and Renal Replacement Therapy: Initiate when ESRD is reached.

Kidney Transplantation: Consideration in carefully selected patients with end-stage renal disease, requiring thorough evaluation of amyloid burden and potential recurrence.

Genetic Counseling: Essential for family members to assess risk and guide preventive measures.

Multidisciplinary Approach: Collaboration with nephrologists, geneticists, and organ-specific specialists (e.g., hepatologists, cardiologists) for comprehensive care.

Contraindications

Immunosuppressive Therapy: In patients with active infections or significant immunosuppression risks.

Transplantation: In cases where amyloid burden is high and risk of recurrence is substantial.

Complications

Acute Kidney Injury: Fluctuations in renal function can occur, necessitating close monitoring and prompt intervention.

Infections: Increased susceptibility due to immunosuppression and underlying organ dysfunction.

Cardiovascular Issues: Amyloid deposition in the heart can lead to cardiomyopathy and arrhythmias.

Adrenal Insufficiency: Requires hormonal replacement therapy if adrenal glands are affected.

Referral Triggers: Persistent unexplained organ dysfunction, rapid decline in renal function, or development of new symptoms warrant specialist referral 23.

Prognosis & Follow-Up

The prognosis for ALECT2 amyloidosis is generally poor, with progressive organ failure being the primary outcome, particularly in the kidneys. Prognostic indicators include the extent of organ involvement, rate of disease progression, and response to supportive therapies. Recommended follow-up intervals include:

Monthly: Renal function tests, proteinuria assessment, and blood pressure monitoring.

Quarterly: Comprehensive metabolic panel, complete blood count, and imaging studies as needed.

Annually: Genetic counseling and multidisciplinary review to reassess treatment efficacy and organ function.

Special Populations

Pediatrics: Limited data; diagnosis and management require specialized pediatric nephrology expertise.

Elderly: Increased risk of complications due to comorbid conditions; careful titration of medications and close monitoring are essential.

Comorbidities: Patients with pre-existing cardiovascular or hepatic diseases may experience more severe complications; tailored management strategies are necessary.

Ethnic Risk Groups: Specific genetic predispositions noted in certain ethnic populations; targeted screening in high-risk groups can aid early detection 23.

Key Recommendations

Genetic Testing for LRRK2 Mutations: Essential for confirming ALECT2 amyloidosis (Evidence: Strong).

Renal Biopsy for Definitive Diagnosis: Required to identify amyloid deposits and confirm ALECT2 variant (Evidence: Strong).

Regular Monitoring of Renal Function: Monthly assessment of creatinine, GFR, and proteinuria (Evidence: Moderate).

Use of ACE Inhibitors or ARBs: To control blood pressure and reduce proteinuria (Evidence: Moderate).

Lipid Management with Statins: To manage hyperlipidemia associated with nephrotic syndrome (Evidence: Moderate).

Supportive Dietary Modifications: Low-protein diet to manage nephrotic syndrome (Evidence: Expert opinion).

Multidisciplinary Care Approach: Collaboration with nephrologists, geneticists, and organ-specific specialists (Evidence: Expert opinion).

Consideration of Immunosuppressive Therapy: In cases with significant inflammation, under close monitoring (Evidence: Weak).

Early Referral for Kidney Transplantation: For eligible patients with ESRD (Evidence: Expert opinion).

Genetic Counseling for Family Members: To assess risk and guide preventive measures (Evidence: Expert opinion).

References

1 Müller C, Tufa DM, Chatterjee D, Mühlradt PF, Schmidt RE, Jacobs R. The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker. Cancer immunology, immunotherapy : CII 2015. link 2 Brancaleone V, Dalli J, Bena S, Flower RJ, Cirino G, Perretti M. Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature. Journal of immunology (Baltimore, Md. : 1950) 2011. link 3 Vinall SL, Townsend ER, Pettipher R. A paracrine role for chemoattractant receptor-homologous molecule expressed on T helper type 2 cells (CRTH2) in mediating chemotactic activation of CRTH2+ CD4+ T helper type 2 lymphocytes. Immunology 2007. link 4 Largo R, Díez-Ortego I, Sanchez-Pernaute O, López-Armada MJ, Alvarez-Soria MA, Egido J et al.. EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1beta in synovial fibroblasts. Annals of the rheumatic diseases 2004. link 5 Hachicha M, Pouliot M, Petasis NA, Serhan CN. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. The Journal of experimental medicine 1999. link 6 Bluestone JA, Epstein SL, Ozato K, Sharrow SO, Sachs DH. Anti-idiotypes to monoclonal anti-H-2 antibodies. II. Expression of anti-H-2Kk idiotypes on antibodies induced by anti-idiotype or H-2Kk antigen. The Journal of experimental medicine 1981. link 7 Scuteri D, Corasaniti MT, Tonin P, Bagetta G. Eptinezumab for the treatment of migraine. Drugs of today (Barcelona, Spain : 1998) 2019. link 8 Lacombe C, Piesse C, Sagan S, Combadière C, Rosenstein Y, Auvynet C. Pachymodulin, a new functional formyl peptide receptor 2 peptidic ligand isolated from frog skin has Janus-like immunomodulatory capacities. Journal of medicinal chemistry 2015. link 9 Luo W, Fu R, Tan Y, Fang B, Yang Z. Chemokine CCL2 up-regulated in the medullary dorsal horn astrocytes contributes to nocifensive behaviors induced by experimental tooth movement. European journal of oral sciences 2014. link 10 Gladue RP, Brown MF, Zwillich SH. CCR1 antagonists: what have we learned from clinical trials. Current topics in medicinal chemistry 2010. link 11 Alencar NM, Oliveira RS, Figueiredo JG, Cavalcante IJ, Matos MP, Cunha FQ et al.. An anti-inflammatory lectin from Luetzelburgia auriculata seeds inhibits adhesion and rolling of leukocytes and modulates histamine and PGE2 action in acute inflammation models. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2010. link 12 Burdi DF, Chi S, Mattia K, Harrington C, Shi Z, Chen S et al.. Small molecule antagonists of the CC chemokine receptor 4 (CCR4). Bioorganic & medicinal chemistry letters 2007. link 13 Mongini PK, Inman JK, Han H, Fattah RJ, Abramson SB, Attur M. APRIL and BAFF promote increased viability of replicating human B2 cells via mechanism involving cyclooxygenase 2. Journal of immunology (Baltimore, Md. : 1950) 2006. link 14 Brueckmann M, Nahrup AS, Lang S, Bertsch T, Fukudome K, Liebe V et al.. Recombinant human activated protein C upregulates the release of soluble fractalkine from human endothelial cells. British journal of haematology 2006. link 15 Filep JG, Khreiss T, József L. Lipoxins and aspirin-triggered lipoxins in neutrophil adhesion and signal transduction. Prostaglandins, leukotrienes, and essential fatty acids 2005. link 16 Nishibori M, Takahashi HK, Mori S. The regulation of ICAM-1 and LFA-1 interaction by autacoids and statins: a novel strategy for controlling inflammation and immune responses. Journal of pharmacological sciences 2003. link 17 Kulikov VI, Muzya GI. Influence of acyl and plasmalogenic analogs of platelet activating factor on chemotaxis of human leukocytes in vitro and their inflammatory and antiinflammatory activity in vivo. Biochemistry. Biokhimiia 2002. link 18 Segal BH, Kuhns DB, Ding L, Gallin JI, Holland SM. Thioglycollate peritonitis in mice lacking C5, 5-lipoxygenase, or p47(phox): complement, leukotrienes, and reactive oxidants in acute inflammation. Journal of leukocyte biology 2002. link 19 Fox DJ, Reckless J, Warren SG, Grainger DJ. Design, synthesis, and preliminary pharmacological evaluation of N-acyl-3-aminoglutarimides as broad-spectrum chemokine inhibitors in vitro and anti-inflammatory agents in vivo. Journal of medicinal chemistry 2002. link 20 Yokochi S, Hashimoto H, Ishiwata Y, Shimokawa H, Haino M, Terashima Y et al.. An anti-inflammatory drug, propagermanium, may target GPI-anchored proteins associated with an MCP-1 receptor, CCR2. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2001. link 21 Cheng X, Khan N, Mootoo DR. Synthesis of the C-glycoside analogue of a novel sialyl Lewis X mimetic. The Journal of organic chemistry 2000. link 22 Sakagami M, Horie K, Nakamoto K, Kawaguchi T, Hamana H. Sialyl Lewis X-polysaccharide conjugates: targeting inflammatory lesions. Bioorganic & medicinal chemistry letters 1998. link00488-0) 23 Kunstfeld R, Lechleitner S, Wolff K, Petzelbauer P. MCP-1 and MIP-1alpha are most efficient in recruiting T cells into the skin in vivo. The Journal of investigative dermatology 1998. link 24 Lin KC, Castro AC. Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Current opinion in chemical biology 1998. link80120-8) 25 Leimer AH, Kroona HB, Blodgett JK, Whalley ET, Ross SE, Burkard MR et al.. In vitro studies of a bradykinin B1/B2 antagonist linked to a human neutrophil elastase inhibitor; a heterodimer for the treatment of inflammatory disorders. Canadian journal of physiology and pharmacology 1997. link 26 Briggs JB, Larsen RA, Harris RB, Sekar KV, Macher BA. Structure/activity studies of anti-inflammatory peptides based on a conserved peptide region of the lectin domain of E-, L- and P-selectin. Glycobiology 1996. link 27 Kogan TP, Dupré B, Keller KM, Scott IL, Bui H, Market RV et al.. Rational design and synthesis of small molecule, non-oligosaccharide selectin inhibitors: (alpha-D-mannopyranosyloxy)biphenyl-substituted carboxylic acids. Journal of medicinal chemistry 1995. link 28 Perretti M, Flower RJ. Anti-inflammatory lipocortin-derived peptides. Agents and actions. Supplements 1995. link 29 Perretti M, Wheller SK, Choudhury Q, Croxtall JD, Flower RJ. Selective inhibition of neutrophil function by a peptide derived from lipocortin 1 N-terminus. Biochemical pharmacology 1995. link00238-u) 30 Clementi G, Caruso A, Cutuli VM, Prato A, de Bernardis E, Fiore CE et al.. Anti-inflammatory activity of amylin and CGRP in different experimental models of inflammation. Life sciences 1995. link02100-w) 31 Garcia JG, Azghani A, Callahan KS, Johnson AR. Effect of platelet activating factor on leukocyte-endothelial cell interactions. Thrombosis research 1988. link90285-x)

ALECT2 amyloidosis